|
Age, years, mean ± SD
|
64.1 ± 10.3
|
|
Male, n (%)
|
26 (81.3)
|
|
Current smoking, n (%)
|
25 (78.1)
|
|
Symptoms, n (%)
|
|
Cough
|
17 (53.1)
|
|
Dyspnea
|
29 (90.6)
|
|
Fever/Fatigue/Chest pain/No symptom
|
11 (11.3)
|
|
Tumor location, n (%)
|
|
Left lung
|
13 (40.6)
|
|
Right lung
|
19 (59.4)
|
|
Tumor histology, n (%)
|
|
squamous
|
9 (28.1)
|
|
adenocarcinoma
|
20 (59.4)
|
|
Squamous+ adenocarcinoma
|
2
|
|
others
|
1 (12.5)
|
|
Initial tumor stage, n (%)
|
|
I-II
|
1 (3.1)
|
|
III-IV
|
31 (96.9)
|
|
ICI agents, n (%)
|
|
pembrolizumab
|
21 (65.6)
|
|
Nivolumab
|
6 (18.8)
|
|
Sintilimab/durvalumab/nivolumab+ipilimumab
|
5 (15.6)
|
|
Surgery, n (%)
|
7 (21.9)
|
|
Chemotherapy, n (%)
|
18 (62.5)
|
|
Radiotherapy, n (%)
|
8 (25.0)
|
|
Radiation pneumonitis, n (%)
|
2 (6.3)
|
|
Prognosis, n (%)
|
|
Survival
|
23 (71.9)
|
|
Death
|
9 (28.1)
|
